Gilead Sciences, Inc. (GILD)
Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish
At this point, Gilead Sciences could only be fairly valued with trading for 10 times free cash flow. With Veklury sales close to a bottom, Gilead Sciences might finally start growing its top line again - acquisition might also contribute to growth. With a dividend yield of 4.5% we are paid to wait until sentiment changes at some day.
Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows
Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and the U.S. economy. On a combination of factors, Gilead may be a top defensive pick to own the rest of 2024.
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
Gilead Sciences has a 4.5% yield. The company has struggled with declining profits and sales in recent years. The company's growth potential lies in its HIV and oncology treatments, but it faces competition and disappointing trial results. Gilead's 4.5% yield and 6% growth potential offer a long-term return potential of 10% to 11%, similar to other dividend ETFs.
3 Biotech Stocks to Buy Now: May 2024
While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Gilead Sciences, Inc. (GILD Quick QuoteGILD - Free Report) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar.ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome proliferator-activated receptor (PPAR) delta agonist or delpar.Seladelpar is a first-in-class oral, selective PPAR-delta agonist or delpar is being evaluated for treating primary biliary cholangitis (PBC).The study enrolled adult patients with PBC who previously participated in a study of seladelpar where a key eligibility criterion included an inadequate response or intolerance to ursodeoxycholic acid (UDCA). Most patients enrolled in ASSURE were female (94%), with a mean age of 59 years.PBC is a rare, chronic, cholestatic liver disease mainly affecting women.We remind investors that the candidate was added to Gilead’s pipeline following the recent acquisition of CymaBay Therapeutics, Inc. The interim results showed that treatment with seladelpar led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with PBC.This analysis did not include patients from the late-stage RESPONSE study, which will be reported separately.The study also evaluated several prespecified biochemical endpoints, including the composite response of alkaline phosphatase (ALP) below 1.67 x upper limit of normal (ULN), a decline in ALP of at least 15% and total bilirubin (TB) below the ULN.70% of patients receiving seladelpar 10mg achieved the clinically meaningful composite endpoint and 37% achieved ALP normalization at 12 months.The reduction in patient-reported pruritus was rapid and durable in patients with moderate to severe symptoms.Please note that a new drug application (NDA) for seladelpar for the treatment of PBC, including pruritus, in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to UDCA is under review in the United States.The FDA granted priority review to the NDA and set a target action date of Aug 14, 2024. The candidate is also under review in Europe.Seladelpar received FDA Breakthrough Therapy Designation for the treatment of PBC, including pruritus in patients without cirrhosis or with compensated cirrhosis and PRIME status (EMA) and Orphan Drug Designation in the United States and Europe for treating patients with PBC.Gilead’s shares have lost 16.4% year to date compared with the industry's decline of 5%. Image Source: Zacks Investment ResearchLast month, GILD reported better-than-expected results for the first quarter of 2024 as its loss was narrower than expected and sales beat estimates.Gilead Sciences, Inc. Price, Consensus and EPS Surprise Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote The company intends to expand its portfolio beyond the HIV franchise. The acquisition of CymaBay complements Gilead’s existing liver portfolio and a potential approval of seladelpar for PBC will strengthen this franchise.Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) received accelerated approval from the FDA in 2016 for the treatment of adult patients living with PBC without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with UDCA with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA.Zacks Rank & Stocks to ConsiderGilead currently carries a Zacks Rank #5 (Strong Sell).A couple of better-ranked stocks from the healthcare industry are Ligand Pharmaceuticals (LGND Quick QuoteLGND - Free Report) and ANI Pharmaceuticals (ANIP Quick QuoteANIP - Free Report) . Both stocks carry a Zacks Rank #2 (Buy). In the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 and 2025 earnings per share (EPS) has remained constant at $4.56 and $5.27, respectively. Shares of LGND are up 20.5% year to date.In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 EPS have improved from $4.43 to $4.44. Shares of ANIP have jumped 11.4% year to date. ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an earnings surprise of 53.90%, on average. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
